Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 6/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.44 |
| ▸ | RIPK3 | Q9Y572 | 3/20 | 0.44 |
| ▸ | BRAF | P15056 | 4/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2458569 | 0.86 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2KDRPDGFRB | |
| SCHEMBL2860133 | 0.85 | KDR (0.55) | RAB9ANPC1SMN1; SMN2KDRPDGFRB | |
| SCHEMBL2452680 | 0.83 | KDR (0.49) | RAB9AKDRPDGFRBKITFLT1 | |
| SCHEMBL2454755 | 0.83 | KDR (0.49) | RAB9ANPC1SMN1; SMN2KDRPDGFRB | |
| SCHEMBL2453000 | 0.82 | KDR (0.52) | RAB9ANPC1SMN1; SMN2KDRPDGFRB | |
| SCHEMBL2458127 | 0.82 | KDR (0.50) | RAB9ASMN1; SMN2KDRPDGFRBKIT | |
| SCHEMBL2454652 | 0.82 | RAB9A (0.54) | RAB9ANPC1SMN1; SMN2KDRPDGFRB | |
| SCHEMBL2452898 | 0.81 | KDR (0.49) | RAB9ANPC1SMN1; SMN2KDRPDGFRB | |
| SCHEMBL2450603 | 0.81 | KDR (0.55) | RAB9ANPC1SMN1; SMN2KDRPDGFRB | |
| SCHEMBL2450659 | 0.80 | KDR (0.54) | RAB9ANPC1SMN1; SMN2KDRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2399921-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-12 | — | — | EP | disclosed |
| EP-2399921-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-12-28 | — | — | EP | disclosed |
| US-20110237620-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237620-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NR3C2, RAF1 | RAB9A 1543/4885NPC1 2884/4885SMN1; SMN2 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.